engleski

Posters

This is the review of our experience in fertility preservation in female patients diagnosed with early stage cancer. The aim of the review was to show, whether cryopreservation prolonges time until chemotherapy. A retrospecitve study was conducted from March 2015 to March 2017 at the Department of Medical Oncology University Hospital for Tumors, Sestre milosrdnice University Hospital Center. Data were collected from medical history. Out of all female patients which were diagnosed with early stage cancer 40 of them wanted to preserve their fertility. Out of total number 38 patents were diagnosed with early stage breast cancer, and two patients were diagosed with colorectal cancer. Patients were between 25 and 43 (median 34) years of age, and they were treated in adjuvant or neoadjuvant sett ing. All patients were off ered with cryopreservation of oocytes or embryos with subcutaneous application of LHRH agonist, or just LHRH agonist application before the start of chemotherapy application or endocrine therapy. Out of 40 patients nine underwent cryopreservation process. Others opted for monthly subcutaneous LHRH agonist application which was conducted during the whole time of chemotherapy application/ endocrine therapy and continued up to three month after last chemotherapy application. Medical record analysis showed that average time from patients presentation at Multdisciplinary team to the fi rst application of chemotherapy was 40.2 days in group that underwent oocyte/embryo cryopreservation, and average time for LHRH group was 21.6 days. Final data of this review is consistent with data available in current literature.

hrčak, hrcak, znanstveni časopisi, hrvatski, scientific journals, croatian

nije evidentirano